ABSTRACT. Lumirubin, a water-soluble photoproduct of bilirubin formed in vivo during phototherapy, is excreted in the urine. In premature infants with little or no bilirubin conjugating activity, lumirubin is the principal yellow pigment found in the urine during phototherapy. The clearance rate of lumirubin in nine premature infants varied from 0.05 to 0.65 ml/min and increased with postconceptional age in parallel with increased creatinine clearance rate. The amount of lumirubin excreted per 24 h was estimated to be from 0.2 to 9.4 mg with a mean of 3.2 mg. The urinary excretion of lumirubin is a significant pathway for pigment elimination during phototherapy. (Pediatr Res 19:
198-201,1985)
Visible light phototherapy has been used to treat neonatal hyperbilirubinemia for more than two decades (1, 2). Although precise data are not available, it has been estimated that between 2 and 5% of all newborn infants are treated with phototherapy (3) . Despite this widespread use over a number of years, the mechanism by which phototherapy lowers serum bilirubin in vivo is not known. The purpose of this study was to determine whether urinary excretion is an important pathway for the elimination of bilirubin photoproducts.
Bilirubin, a metabolic product of heme degradation (4), is a highly lipophilic molecule (5); prior to excretion, bilirubin is made more water soluble by conjugation to glucuronic acid (6) .
Because newborn infants are deficient in the enzyme@) responsible for this conjugation reaction they frequently develop hyperbilirubinemia which is most often treated with phototherapy. During phototherapy, bilirubin undergoes two principal photochemical reactions, which yield products that are more polar than the native molecule (7) (8) (9) (10) . The relative importance of these two reactions to the therapeutic response seen with phototherapy depends on both the rates of formation and the rates of excretion of the photoproducts.
The two principal photoproducts are 42,l SE-bilirubin, a configurational isomer of the native 4Z, 15Z-bilirubin (9), and lumirubin, a structural isomer which contains a seven-member ring (10) (Fig. I ). The relative rates of the two reactions are known from in vitro studies (9-1 1) and appear to be similar in vivo (12) . The faster reaction is the configurational isomerization which is freely reversible. The formation of lumirubin occurs more slowly (1 1) but is essentially irreversible. Typically during phototherapy, 2 to 6% of the total bilirubin is present as lumirubin whereas 15 to 20% is present as the configurational isomer (12) . A third type of reaction, the photooxidation of bilirubin to mono and dipyrroles (1 3) occurs at a much lower rate than either isomerization reaction (1 1) and is not thought to be a quantitatively important pathway for bilirubin elimination.
The decline in serum bilirubin during phototherapy requires not only formation of these bilirubin isomers but also their elimination. The principal route of photoproduct elimination is thought to be through the bile. Onishi et al. (8) have reported finding a bilirubin photoproduct, which they called "unknown pigment," in the bile and urine of infants treated with phototherapy. We have used a high pressure liquid chromatographic method to quantitate the urinary excretion of bilirubin isomers in nine preterm infants. We have identified the photoproduct in the urine as the configurational isomer of bilirubin, lumirubin. We have determined the rate of urinary excretion of lumirubin clearance rate.
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and have found that it can account for only a fraction of the Figure 2 contains chromatograms of urine from a preterm total bilirubin eliminated during phototherapy.
infant obtained prior to the start of phototherapy (upper chromatogram) and after 8 h of phototherapy (lower chromatogram).
METHODS
Prior to phototherapy, the urine of preterm infants contains little Nine preterm infants were studied. The characteristics of the study population are given in Table 1 . During the collection period, the infants were treated with continuous phototherapy from a band of eight daylight fluorescent tubes housed in a standard phototherapy canopy. Urine was collected over a 24-h period in plastic neonatal urine collection bags, which were shielded from light during the collection by diapering the infant. The urine was kept in foil-wrapped containers until the collection was complete, then it was stored frozen until analyzed. During the 24-h collection period a blood sample was obtained under subdued lighting conditions and immediately placed in a foilwrapped tube. Creatinine concentration in urine and in serum was measured in the clinical chemistry laboratory at University Hospitals of Cleveland by standard techniques. All other work with serum and urine was done under photographic safelight.
Bilirubin photoproducts in serum and urine were analyzed by reversed-phase high pressure liquid chromatography on a 0.46 x 25 cm Zorbax-ODs column (DuPont Instruments) equipped with a precolumn to trap the denatured protein from the serum samples. The eluant was 0.1 M di-n-octylamine acetate in methanol, pH 7.7 at a flow rate of 0.7 ml/min (9). Analyses were done on a Varian model 5060 liquid chromatograph equipped with a model UV-100 detector set at 465 nm or with a HewlettPackard model 1040A high speed scanning spectrophotometric detector with simultaneous monitoring at eight wavelengths including 450 and 465 nm. The concentrations of bilirubin and bilirubin photoproducts were quantified from chromatographic peak areas by a Hewlett-Packard model 3390A reporting integrator monitoring the absorbance at 465 nm. The relative 465 nm extinction coeficients for 4Z,15Z-bilirubin:4Z, 15E-bilirubin:lumirubin in 0.1 M di-n-octylamine acetate in methanol are 1.0:0.92:0.42. These factors, which were used to correct the integrated peak areas on the chromatograms, were calculated from absorption spectra of the various isomers which were normalized at an isosbestic point. The identification of the photoproducts were based on chromatographic retention times and by absorption spectra obtained during chromatography by the high speed scanning spectrophotometric detector.
Clearances of creatinine and lumirubin were calculated by the standard formula: urine concentration X urine volume Clearance = plasma concentration
The clearance results are expressed in ml/min. Bilirubin levels were measured at least twice per day by standard spectrophotomaterial which absorbs 450 nm light (i.e., yellow pigment). After initiation of phototherapy, a yellow pigment appears in the urine. Identification of this photoproduct in the urine as the structural isomer, lumirubin, is based on the following: the urinary pigment has the same chromatographic retention time and the same absorption profile as lumirubin prepared by irradiation of bilirubin in vitro and purified as described by McDonagh et al. (10) .
In the absence of conjugates of bilirubin, lumirubin is the only yellow pigment excreted into the urine. The clearance rates for lumirubin were measured in nine preterm infants and are plotted in Figure 3 as a function of postconceptional age (gestational plus postnatal age). For comparison, the creatinine clearance rates were simultaneously measured and the results (Fig. 3) were similar to those reported by Arant (14) for preterm infants. The clearance rate for lumirubin varied from 0.05 to 0.65 ml/min and increased with postconceptional age (r = 0.70, p < 0.05). The lumirubin clearance and creatinine clearance were highly correlated (r = 0.96, p < 0.01), with lumirubin clearance a consistent fraction (8 & 4%) of creatinine clearance. The study sample was too small to distinguish the effect of postnatal age from the effect of gestational age on the clearance rates (14) . The amount of lumirubin excreted in the urine per 24 h ranged from 0.2 to 9.4 mg with a mean of 3.2 mg.
Our results confirm the observation of Onishi et al. (8) that lumirubin is excreted in the urine of infants treated with phototherapy. Moreover, we have found that in premature infants with little or no bilirubin conjugating activity lumirubin is the principal yellow pigment excreted in the urine during phototheraPY Lumirubin excretion in the urine must contribute to the therapeutic response to phototherapy; however, it does not account for the total pigment elimination during phototherapy. The total amount of bilirubin removed during phototherapy can only be estimated for the patients we studied. In the absence of a change in the total amount of bilirubin, elimination would equal production, which has been estimated to be 8.5 mg/kg/ day in newborn infants (1 5). Using this estimate, bilirubin production in our study population would range from 6 to 25 mg/ day, which is greater than the urinary excretion rate of lumirubin we measured in these preterm infants (0.2 to 9.4 mg/day).
Although lumirubin elimination in the urine is not responsible for the total excretion of pigment during phototherapy, it may KNOX ET AL. ]bilirubin, 18 to 28% of the excreted radioactivity were found in the urine (72 to 82% was in the stool). However, no diazo-positive material (intact bilirubin or bilirubin configurational isomers) was found in the urine. Although no chemical identification or structural analysis of the pigment derivatives was done by these investigators, the excreted ['4C]labeled pigment most likely was lumirubin and photooxidation products, with lumirubin predominating because of its much faster rate of formation (1 1). If the mechanism of bilirubin elimination in premature infants is the same as in the older children with Crigler-Najjar syndrome studied by Callahan et al. (1 6), then as much as one-fourth of the pigment excreted during phototherapy may be the result of urinary clearance of lumirubin.
Lumirubin is formed from bilirubin by a photochemically irreversible reaction (Fig. 1) . We have recently shown that the concentration of lumirubin in the serum of jaundiced infants can be increased by the use of higher intensity illumination during phototherapy (12) , presumably from increased production. Furthermore, it may be possible to increase lumirubin production through use of selected wavelengths of light which favor formation of lumirubin over other photoproducts (17) . Thus, increased intensity phototherapy with selected wavelengths of light may improve the efficacy of phototherapy and make phototherapy useful in clinical settings in which hepatic function is impaired.
